<?xml version="1.0" encoding="UTF-8"?>
<p>An ideal alternative to hyperimmune sera is monoclonal antibodies owing to their specific pharmacological and safety profiles (Traggiai et al., 2004; Li et al., 2006). Hybridoma technology allows the production of monoclonal antibodies against specific target antigens, in large quantities in the laboratory environment. </p>
